Judit OlÃ;h

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3578672/publications.pdf

Version: 2024-02-01

40 papers 1,776 citations

331538
21
h-index

39 g-index

41 all docs

41 docs citations

41 times ranked

2656 citing authors

#	Article	IF	Citations
1	Challenges in Discovering Drugs That Target the Protein–Protein Interactions of Disordered Proteins. International Journal of Molecular Sciences, 2022, 23, 1550.	1.8	16
2	Co-Transmission of Alpha-Synuclein and TPPP/p25 Inhibits Their Proteolytic Degradation in Human Cell Models. Frontiers in Molecular Biosciences, 2021, 8, 666026.	1.6	9
3	Anti-Aggregative Effect of the Antioxidant DJ-1 on the TPPP/p25-Derived Pathological Associations of Alpha-Synuclein. Cells, 2021, 10, 2909.	1.8	1
4	HaloTagâ€Targeted Sirtuinâ€Rearranging Ligand (SirReal) for the Development of Proteolysisâ€Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)**. ChemBioChem, 2020, 21, 3371-3376.	1.3	13
5	Microtubule-Associated Proteins with Regulatory Functions by Day and Pathological Potency at Night. Cells, 2020, 9, 357.	1.8	23
6	Interactions between two regulatory proteins of microtubule dynamics, HDAC6, TPPP/p25, and the hub protein, DYNLL/LC8. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 118556.	1.9	4
7	Pharmacological targeting of αâ€synuclein and TPPP /p25 in Parkinson's disease: challenges and opportunities in a Nutshell. FEBS Letters, 2019, 593, 1641-1653.	1.3	11
8	Localization of the zinc binding tubulin polymerization promoting protein in the mice and human eye. Journal of Trace Elements in Medicine and Biology, 2018, 49, 222-230.	1.5	4
9	Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). Journal of Medicinal Chemistry, 2018, 61, 482-491.	2.9	204
10	Tubulin Binding and Polymerization Promoting Properties of Tubulin Polymerization Promoting Proteins Are Evolutionarily Conserved. Biochemistry, 2017, 56, 1017-1024.	1.2	18
11	Role of the microtubule-associated TPPP/p25 in Parkinson's and related diseases and its therapeutic potential. Expert Review of Proteomics, 2017, 14, 301-309.	1.3	18
12	Challenging drug target for Parkinson's disease: Pathological complex of the chameleon TPPP/p25 and alpha-synuclein proteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 310-323.	1.8	23
13	Modulation Of Microtubule Acetylation By The Interplay Of TPPP/p25, SIRT2 And New Anticancer Agents With Anti-SIRT2 Potency. Scientific Reports, 2017, 7, 17070.	1.6	17
14	Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure–Activity Relationship Study. Journal of Medicinal Chemistry, 2016, 59, 1599-1612.	2.9	76
15	Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nature Communications, 2015, 6, 6263.	5.8	222
16	Targeting the interface of the pathological complex of \hat{l}_{\pm} -synuclein and TPPP/p25. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2653-2661.	1.8	18
17	Zinc-induced structural changes of the disordered tppp/p25 inhibits its degradation by the proteasome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 83-91.	1.8	9
18	Modeling of sensing potency of cytoskeletal systems decorated with metabolic enzymes. Journal of Theoretical Biology, 2015, 365, 190-196.	0.8	4

#	Article	IF	Citations
19	Identification of motives mediating alternative functions of the neomorphic moonlighting TPPP/p25. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 547-557.	1.8	25
20	Dual life of TPPP/p25 evolved in physiological and pathological conditions. Biochemical Society Transactions, 2014, 42, 1762-1767.	1.6	11
21	Microtubule assembly-derived by dimerization of TPPP/p25. Evaluation of thermodynamic parameters for multiple equilibrium system from ITC data. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 785-794.	1.1	12
22	A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. Biochemical and Biophysical Research Communications, 2011, 409, 137-141.	1.0	22
23	Reappraisal of triosephosphate isomerase deficiency. European Journal of Haematology, 2011, 86, 265-267.	1.1	5
24	Disordered TPPP/p25 binds GTP and displays Mg ²⁺ -dependent GTPase activity. FEBS Letters, 2011, 585, 803-808.	1.3	26
25	Zn ²⁺ -Induced Rearrangement of the Disordered TPPP/p25 Affects Its Microtubule Assembly and GTPase Activity. Biochemistry, 2011, 50, 9568-9578.	1.2	25
26	Interactions of Pathological Hallmark Proteins. Journal of Biological Chemistry, 2011, 286, 34088-34100.	1.6	138
27	Tubulin polymerization promoting protein (TPPP/p25) as a marker for oligodendroglial changes in multiple sclerosis. Glia, 2010, 58, 1847-1857.	2.5	61
28	TPPP/p25 Promotes Tubulin Acetylation by Inhibiting Histone Deacetylase 6. Journal of Biological Chemistry, 2010, 285, 17896-17906.	1.6	91
29	Synthesis and in Vitro Antitumor Effect of Vinblastine Derivativeâ°'Oligoarginine Conjugates. Bioconjugate Chemistry, 2010, 21, 1948-1955.	1.8	25
30	Triosephosphate isomerase deficiency: New insights into an enigmatic disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 1168-1174.	1.8	126
31	TPPP/p25: A New Unstructured Protein Hallmarking Synucleinopathies. Focus on Structural Biology, 2009, , 225-250.	0.1	5
32	Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS Journal, 2008, 275, 4740-4755.	2.2	60
33	Triosephosphate isomerase deficiency: Facts and doubts. IUBMB Life, 2006, 58, 703-715.	1.5	101
34	Tubulin Polymerization Promoting Proteins (TPPPs): Members of a New Family with Distinct Structures and Functionsâ€. Biochemistry, 2006, 45, 13818-13826.	1.2	83
35	Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Letters, 2006, 580, 5807-5814.	1.3	34
36	Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels. Biochemical Journal, 2005, 392, 675-683.	1.7	40

Judit OlÃih

#	Article	IF	CITATION
37	Phosphoenolpyruvate-dependent Tubulin-Pyruvate Kinase Interaction at Different Organizational Levels. Journal of Biological Chemistry, 2003, 278, 7126-7130.	1.6	22
38	Triosephosphate isomerase deficiency: a neurodegenerative misfolding disease. Biochemical Society Transactions, 2002, 30, 30-38.	1.6	50
39	Brain-Specific p25 Protein Binds to Tubulin and Microtubules and Induces Aberrant Microtubule Assemblies at Substoichiometric Concentrations. Biochemistry, 2002, 41, 8657-8664.	1.2	121
40	A Potential Innovative Therapy for Parkinson's Disease: Selective Destruction of the Pathological Assemblies of Alpha-Synuclein. , 0, , .		3